Committed to Patients. Driven to Discover.

At Bristol Myers Squibb, we are driven by the discovery of science that may transform the lives of cancer patients.

Until we can meet again, please explore our earlier stages* of cancer pipeline below.

Oncology Earlier Stages of Cancer Pipeline

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country. Information as of May 2021.

	Modality	Area of Research	Phase
Breast			
⚭ Nivolumab + CDK inhibitor + aromatase inhibitor	Anti–PD-1 + CDK inhibitor + aromatase inhibitor	Neoadjuvant ER+/HER2- breast cancer	2
⚭ Nivolumab + chemo followed by nivolumab + endocrine therapy	Anti–PD-1	Neoadjuvant/adjuvant high-risk breast cancer	3
Gastrointestinal			
Nivolumab	Anti–PD-1	Adjuvant esophageal or GEJ cancer	3
Nivolumab	Anti–PD-1	Adjuvant HCC	3
⚭ Nivolumab + TACE ± ipilimumab	Anti–PD-1 ± anti–CTLA-4	Intermediate stage HCC	3
Genitourinary			
Nivolumab	Anti–PD-1	Adjuvant invasive high-risk urothelial carcinoma	3
Nivolumab ± ipilimumab	Anti–PD-1 ± anti–CTLA-4	Adjuvant RCC	3
⚭ Nivolumab + BCG	Anti–PD-1 + BCG	BCG relapsed or refractory high-risk NMIBC	3
⚭ Nivolumab + BCG + linrodostat mesylate	Anti–PD-1 + BCG + IDO1 inhibitor	BCG relapsed or refractory high-risk NMIBC	2
⚭ Nivolumab ± BCG	Anti–PD-1 ± BCG	BCG relapsed or refractory high-risk NMIBC	2
⚭ Nivolumab + linrodostat mesylate ± BCG	Anti–PD-1 + IDO1 inhibitor ± BCG	BCG relapsed or refractory high-risk NMIBC	2
⚭ Nivolumab ± bempegaldesleukin (NKTR-214)	Anti–PD-1 ± CD122 preferential IL-2 pathway agonist	Peri-operative MIBC	3
⚭ Nivolumab + chemo ± linrodostat mesylate	Anti–PD-1 ± ID01 inhibitor	Peri-operative MIBC	3
Head & Neck			
Nivolumab + motolimod	Anti–PD1 + TLR8 agonist	1L resectable SCCHN	1
Lung			
⚭ Nivolumab ± ipilimumab ± chemo	Anti–PD-1	Early-stage, resectable NSCLC (≥4 cm)	3
⚭ Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab	Anti–PD-1	Resectable early-stage (stage II-IIIB) NSCLC (≥4 cm)	3
⚭ Nivolumab + chemo + RT, followed by maintenance nivolumab + ipilimumab	Anti–PD-1 ± anti–CTLA-4	1L locally advanced NSCLC amenable to cCRT	3
Melanoma			
Nivolumab	Anti–PD-1	Adjuvant stage IIB/C melanoma	3
⚭ Nivolumab ± bempegaldesleukin (NKTR-214)	Anti–PD-1 ± CD122-preferential IL-2 pathway agonist	Adjuvant fully resected melanoma in patients at high risk for recurrence	3

⚭ = Trial investigates BMS agent(s) in combination with 1 or more non–BMS-owned assets. Development partnerships include:
- Bempegaldesleukin: Nektar

*Non-metastatic or resectable metastatic.

cCRT=concurrent chemoradiotherapy; CDK=cyclin-dependent kinase; chemo=chemotherapy; CTLA-4=cytotoxic T-lymphocyte antigen 4; ER=estrogen receptor; GBM=glioblastoma multiforme; GEJ=gastroesophageal junction; HCC=hepatocellular carcinoma; HER2=human epidermal growth factor receptor 2; ID01=indoleamine 2,3-deoxygenate-1; IL-2=interleukin-2; MIBC=muscle-invasive bladder cancer; NMIBC=non–muscle-invasive bladder cancer; NSCLC=non–small cell lung cancer; PD-1=programmed death receptor-1; RCC=renal cell carcinoma; SCCHN=squamous cell carcinoma of the head and neck; TACE=transarterial chemoembolization.

Bristol Myers Squibb™

© 2021 Bristol Myers Squibb ONC-US-2100378 05/21